Tag Archives: Biotech

Biotech Stocks Shaken by Fed Warning

Today’s Financial Times (FT) reports that nearly $40bn was wiped from the biotech market’s value last week (a 6 per cent drop in the Nasdaq biotechnology index) following the Federal Reserve’s identification of biotech shares as a cause for concern. There was some recovery on Friday however when prices rebounded 3 per cent. The US […]
Posted in Biotech | Also tagged , | Leave a comment

Rise in IPOs Eases Pharma's Investment Woes

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
Posted in Biotech, Deals, Global, healthcare | Also tagged , , , , | Leave a comment

Time for Russia to Get Serious about Biopharma

Back in 1980, the biotech industry did not exist. There was little difference between the means of production in Western markets and the socialist planned economies embodied by Russia – medicines, still a low-tech purchase, played a modest role in the delivery of health care in both sectors. What happened in the ensuing decades has […]
Posted in Biotech, Emerging Markets, Europe, Global, Strategy | Also tagged , , | 1 Comment

Prove It! Top Line Thoughts on Trends That Will Shape the Industry in 2014

Top Line Thoughts on 2014:  Prove It! Ten days in and the New Year already seems old.  Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets – forward and backward – over the busy […]
Posted in Biotech, Strategy | Also tagged , , , | Leave a comment

Lessons from Biotech: Tweaking the Imperfections

An increasing number of small biotech companies are being hatched to focus on a single disease or condition. The strategy goes against the diversified portfolio approach most big pharma companies have embraced, and instead puts all the eggs in one basket. Dart Therapeutics—one such company—has taken on Duchenne Muscular Dystrophy (DMD), a disease found in […]
Posted in Biotech, Orphan Drugs, R&D, Strategy | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta